JP7811578B2 - 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 - Google Patents

中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Info

Publication number
JP7811578B2
JP7811578B2 JP2023515095A JP2023515095A JP7811578B2 JP 7811578 B2 JP7811578 B2 JP 7811578B2 JP 2023515095 A JP2023515095 A JP 2023515095A JP 2023515095 A JP2023515095 A JP 2023515095A JP 7811578 B2 JP7811578 B2 JP 7811578B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
alkenyl
optionally substituted
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515095A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022051583A5 (https=
JP2023540350A5 (https=
JP2023540350A (ja
Inventor
ブルース レフカー
ゴードン サクスティ
カール ギブソン
マーク ピックワース
マシュー スペンディフ
マイルズ コングリーブ
ポール ハンフリーズ
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2023540350A publication Critical patent/JP2023540350A/ja
Publication of JPWO2022051583A5 publication Critical patent/JPWO2022051583A5/ja
Publication of JP2023540350A5 publication Critical patent/JP2023540350A5/ja
Application granted granted Critical
Publication of JP7811578B2 publication Critical patent/JP7811578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023515095A 2020-09-03 2021-09-03 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 Active JP7811578B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074220P 2020-09-03 2020-09-03
US63/074,220 2020-09-03
PCT/US2021/049003 WO2022051583A1 (en) 2020-09-03 2021-09-03 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Publications (4)

Publication Number Publication Date
JP2023540350A JP2023540350A (ja) 2023-09-22
JPWO2022051583A5 JPWO2022051583A5 (https=) 2024-10-02
JP2023540350A5 JP2023540350A5 (https=) 2024-10-02
JP7811578B2 true JP7811578B2 (ja) 2026-02-05

Family

ID=78078371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515095A Active JP7811578B2 (ja) 2020-09-03 2021-09-03 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Country Status (6)

Country Link
US (1) US20230331720A1 (https=)
EP (1) EP4208465A1 (https=)
JP (1) JP7811578B2 (https=)
CN (1) CN116635393A (https=)
TW (1) TW202227433A (https=)
WO (1) WO2022051583A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2022280804A1 (en) * 2021-05-26 2023-11-30 Alkermes, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
JP2025507852A (ja) * 2022-03-01 2025-03-21 センテッサ ファーマシューティカルズ （ユーケー） リミテッド 中環状または大環状ベンジル置換複素環誘導体および関連の使用
IL316468A (en) * 2022-04-22 2024-12-01 Teijin Pharma Ltd The aftermath of oxazepine
CN114716319B (zh) * 2022-04-28 2024-03-26 浙江工业大学 一种联芳氧基烯酸酯类化合物的合成方法
WO2024075825A1 (ja) * 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4611745A1 (en) 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
PE20252742A1 (es) 2023-03-16 2025-12-05 Takeda Pharmaceuticals Co Compuestos heterociclicos macrociclicos y sus usos
IL324946A (en) 2023-06-01 2026-01-01 H Lundbeck As Spiro-macrocyclic orexin 2 receptor agonists
EP4719397A1 (en) 2023-06-02 2026-04-08 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
TW202535890A (zh) * 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527688A (ja) 2017-08-03 2019-10-03 武田薬品工業株式会社 複素環化合物およびその用途
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP4065585B1 (en) * 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527688A (ja) 2017-08-03 2019-10-03 武田薬品工業株式会社 複素環化合物およびその用途
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Also Published As

Publication number Publication date
CN116635393A (zh) 2023-08-22
WO2022051583A1 (en) 2022-03-10
EP4208465A1 (en) 2023-07-12
JP2023540350A (ja) 2023-09-22
TW202227433A (zh) 2022-07-16
US20230331720A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
JP7840517B2 (ja) 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN107573332B (zh) 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN114641473A (zh) Brd9双官能团降解剂及其使用方法
CN115836072A (zh) Kras g12c蛋白的抑制剂和其用途
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
JP2023534983A (ja) テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法
JP6532599B2 (ja) ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
CN101094848A (zh) 有机化合物
TW201706275A (zh) 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
JP6954921B2 (ja) ブロモドメイン阻害薬としてのピリジル誘導体
CN114874209B (zh) 噁二唑瞬时受体电位通道抑制剂
WO2020063824A1 (zh) 硝羟喹啉前药及其用途
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
CN117042769A (zh) 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
US20250236629A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
WO2024125627A1 (zh) 喜树碱类化合物及其制备方法和用途
WO2020192652A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用
CN115768772A (zh) 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吡喃并[4,3-b]L吲哚衍生物
TW202430522A (zh) 一種用於ｂｃｌ－２蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用
TW202333663A (zh) Rxfp1促效劑
WO2025108255A1 (zh) 一种多环类衍生物、其制备方法和应用
CN106458987B (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
CN115448882A (zh) 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240902

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240904

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260126

R150 Certificate of patent or registration of utility model

Ref document number: 7811578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150